HIV
M-A | Desfechos perinatais adversos associados com terapia antirretroviral baseada em inibidor de protease em gestantes vivendo com HIV.
14 Abr, 2022 | 17:32hComunicado de imprensa: Protease inhibitors safer than thought for pregnant women with HIV – University of Oxford
Estudo randomizado | Para adultos vivendo com HIV, uma estratégia de tratamento de 4-dias-sim e 3-dias-não é não inferior ao tratamento padrão para manter a supressão viral.
12 Abr, 2022 | 12:45hA 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial – The Lancet HIV (link para o resumo – $ para o texto completo)
Comentário: Intermittent Treatment Strategy Is Effective for HIV – Consultant360
Comentário no Twitter
New: A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial by Roland Landman and colleagues https://t.co/Tc2Rbo1ISt pic.twitter.com/YTV3XwfELo
— The Lancet HIV (@TheLancetHIV) February 3, 2022
In virologically suppressed people with HIV, randomization to intermittent ART (4 days on, 3 off) was non-inf. to daily dosing. Challenges what I thought about level of adherence needed. Is good adherence only needed during the viremic phase? https://t.co/lM8QZW0C9h
— David Serota (@serotavirus) March 16, 2022
Estudo randomizado | Cabotegravir (injeções intramusculares a cada 8 semanas) na prevenção de HIV-1 em mulheres.
8 Abr, 2022 | 17:25hCabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial – The Lancet (link para o resumo – $ para o texto completo)
Conteúdos relacionados:
FDA approves first injectable treatment for HIV pre-exposure prevention.
RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.
Revisão sistemática | Rastreamento de sintomas e radiografia torácica para identificar tuberculose pulmonar ativa em adultos HIV-negativos e adultos com status de HIV desconhecido.
29 Mar, 2022 | 14:05hPrimeiro caso de cura do HIV em uma mulher após transplante de célula tronco relatado no CROI-2022.
29 Mar, 2022 | 13:57hM-A | Rastreamento da tuberculose entre pacientes HIV-positivos internados.
25 Mar, 2022 | 15:30h
Comentário no Twitter
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis https://t.co/DqTUr2JxHy In setting where TB prevalence is > 10%, WHO now strongly recommends molecular rapid diagnostic testing in all medical inpatient PWH.
— Carlos del Rio (@CarlosdelRio7) March 24, 2022
Estudo randomizado | Tratamento com dose única de anfotericina B lipossomal para meningite por criptococo.
25 Mar, 2022 | 15:01hSingle-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Cryptococcal meningitis is a major complication of HIV infection. Single-dose liposomal amphotericin B combined with flucytosine and fluconazole was noninferior to the WHO-recommended treatment and was associated with fewer adverse events. https://t.co/cg9DqSDhyN pic.twitter.com/SrKx4tDaph
— NEJM (@NEJM) March 23, 2022
Revisão sistemática | Testes rápidos de carga viral para detectar alta carga viral de HIV em pessoas que vivem com HIV/AIDS em instituições de saúde.
14 Mar, 2022 | 13:48hM-A | Desfechos de pessoas portadoras de HIV após alta hospitalar.
10 Mar, 2022 | 15:31h
Comentário no Twitter (fio – clique para saber mais)
New: Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis by Nathan Ford and colleagues https://t.co/5xurY4Sxm0 #openaccess
— The Lancet HIV (@TheLancetHIV) March 3, 2022
Série Lancet | Envelhecimento com HIV.
8 Mar, 2022 | 17:38hPágina principal: Ageing with HIV
Editoriais:
Séries:
Delayed presentation of HIV among older individuals: a growing problem
How health systems can adapt to a population ageing with HIV and comorbid disease
Biological ageing with HIV infection: evaluating the geroscience hypothesis